Basel, Switzerland – 10 February 2026
We warmly welcome Dr Seng Chin Mah to the Akceso Board of Directors
Akceso Advisors AG, a leading independent global advisory firm specializing in market access, pricing, reimbursement strategy, operations and policy-setting for life-science companies and authorities, announced today the election of Dr. Seng Chin Mah as a new non‑executive member of its Board of Directors.
Dr. Mah brings more than 30 years of senior leadership experience in the pharmaceutical and biotech industries across public and privately held companies. His extensive background spans corporate governance, late-stage clinical development, regulatory strategy and global biotech leadership across several successful ventures.
“We are honored to welcome Dr. Mah to Akceso Advisors AG’s Board,” said Dr. Andras Incze CEO, Founder, and Chairman of the Board. “His exceptional track record in strategic decision-making and executive leadership in successful biotech ventures will provide invaluable guidance as we further expand our global reach and continue to support our clients navigating today’s increasingly unpredictable business environment, addressing the complex market access challenges that increasingly impact pharmaceutical development.”
Dr. Mah is Chairman of BioVersys AG (SIX‑listed), and sits on the boards of OSR Holdings Inc. (NASDAQ‑listed) and Vaccentis AG. He was previously Chief Executive Officer of the Canyon Pharmaceuticals Group AG, where he successfully transacted a corporate inversion of a U.S.-registered company to Switzerland.
Earlier in his career, Dr. Mah held a series of senior leadership roles at Novartis and Ciba, including Global Head of Clinical Safety and Epidemiology, Head of Drug Regulatory Affairs Europe, and Head of the Development Integration Office during the integration of Chiron into Novartis. He was a member of the Novartis Corporate Executive Group and the Board of Directors of Novartis Europharm Ltd. in the UK.
Dr. Mah is an award‑winning biotech leader, having received the Frost & Sullivan 2011 Product Differentiation Excellence Award in Parenteral Anticoagulants for leading Canyon Pharmaceuticals in the development and launch of Iprivask® (desirudin for injection). He subsequently oversaw the successful asset transaction of the product.
“I am delighted to join the Board of Akceso Advisors,” said Dr. Seng Chin Mah. “The company has built an exceptional reputation for professional rigor, strategic insight and sophisticated cloud-based tools, and is committed to improving patient access to innovative therapies. I look forward to contributing to its continued growth and mission.”
About Akceso Advisors
Akceso Advisors AG is an independent, global advisory firm dedicated to supporting life-science companies and authorities in developing and implementing evidence‑based market access, pricing, and reimbursement strategies and policies, living up to its motto of being Catalysts to Patient Access and Pricing Success – For Better Public Health Worldwide. With an experienced senior team, deep practical experience across most healthcare systems at a global, regional and local level, strong scientific expertise, analytical strength and sophisticated AI-integrated tools, Akceso Advisors enables its clients to optimize patient access to innovative medicines and technologies – for today’s patients, and tomorrow’s.
For more information, visit https://akceso.ch
Media Contact
Akceso Advisors AG
ask@akceso.ch
